NanoString Technologies Inc. (NSTG) Jumps 6.07% on January 18

Equities Staff |

NanoString Technologies Inc. (NSTG) was among the biggest gainers on the Russell 2000 for Monday January 18 as the stock popped 6.07% to $14.33, representing a gain of $0.82 per share. Some 224,563 shares traded hands on 2,510 trades, compared with an average daily volume of 125,462 shares out of a total float of 19.51 million. The stock opened at $13.10 and traded with an intraday range of $14.72 to $12.41.

After today's gains, NanoString Technologies Inc. reached a market cap of $279.53 million. NanoString Technologies Inc. has had a trading range between $19.81 and $9.95 over the last year, and it had a 50-day SMA of $14.16 and a 200-day SMA of $14.52.

NanoString Technologies Inc develops, manufactures and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue.

NanoString Technologies Inc. is based out of Seattle, WA and has some 276 employees. Its CEO is R. Bradley Gray.

For a complete fundamental analysis analysis of NanoString Technologies Inc., check out’s Stock Valuation Analysis report for NSTG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…